Drugs / TQD3524
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07512596 | Jul 2026 → Jul 2027 expected | bacterial pneumonia | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06522945 Comparator | Jul 2024 → Dec 2025 | gram-negative bacterial infections | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQD3524 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07512596 ↗ |
| Route | Intravenous | “intravenous drip” NCT07512596 ↗ |